FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084060246> ?p ?o ?g. }

• W2084060246 endingPage "24" @default.
• W2084060246 startingPage "19" @default.
• W2084060246 abstract "Type 2 diabetes mellitus (T2DM) is associated with a high risk for coronary heart disease (CHD). A variety of lipoprotein and apolipoprotein (Apo) ratios have been proposed that may reflect the balance of cholesterol delivery and removal at the arterial wall and provide an assessment of CHD risk that is supplemental to low-density lipoprotein cholesterol (LDL-C), the primary guide for cholesterol-lowering therapy in patients at risk.To examine changes in lipoprotein and apolipoprotein ratios in the VYTAL trial of hypercholesterolemic patients with T2DM.Changes in the ratios LDL-C/high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC)/HDL-C, non-HDL-C/HDL-C, and ApoB/ApoA-I were assessed in this randomized, double-blind, parallel-group study that enrolled T2DM patients with LDL-C ≥100 mg/dL for 6-week treatments with either the usual daily starting doses of atorvastatin (ATORVA) 10 or 20 mg or ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg, or the next highest doses (ATORVA 40 mg, EZE/SIMVA 10/40 mg). Changes in lipoprotein and apolipoprotein ratios, prespecified exploratory endpoints, were analyzed using analysis of variance.Efficacy results were based on 1198 patients with sufficient data among 1229 randomized patients. Baseline lipoproteins, apolipoproteins, and ratios were comparable among treatment groups. EZE/SIMVA produced significantly greater reductions compared with ATORVA in each lipoprotein or apolipoprotein ratio at each dose comparison (P < 0.001). For example, reductions from baseline in TC/HDL-C were ATORVA 10 mg, -30.2%; ATORVA 20 mg -34.9%; EZE/SIMVA 10/20 mg, -41.6%; ATORVA 40 mg, -37.9%; and EZE/SIMVA 10/40 mg, -43.5%. Tolerability of the two treatments was similar.For the doses assessed, EZE/SIMVA was more effective compared with ATORVA in lowering the lipoprotein and apolipoprotein ratios that might be considered secondary measures of CHD risk." @default.
• W2084060246 created "2016-06-24" @default.
• W2084060246 creator A5008726377 @default.
• W2084060246 creator A5011389314 @default.
• W2084060246 creator A5023716582 @default.
• W2084060246 creator A5062468141 @default.
• W2084060246 creator A5080916339 @default.
• W2084060246 creator A5086425417 @default.
• W2084060246 creator A5090460841 @default.
• W2084060246 date "2008-02-01" @default.
• W2084060246 modified "2023-09-23" @default.
• W2084060246 title "Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes" @default.
• W2084060246 cites W1886627904 @default.
• W2084060246 cites W1979370910 @default.
• W2084060246 cites W1987899716 @default.
• W2084060246 cites W1988251445 @default.
• W2084060246 cites W2007002950 @default.
• W2084060246 cites W2014759828 @default.
• W2084060246 cites W2027874774 @default.
• W2084060246 cites W2028219942 @default.
• W2084060246 cites W2031185570 @default.
• W2084060246 cites W2040462758 @default.
• W2084060246 cites W2045054080 @default.
• W2084060246 cites W2051882247 @default.
• W2084060246 cites W2059403223 @default.
• W2084060246 cites W2063824141 @default.
• W2084060246 cites W2069215018 @default.
• W2084060246 cites W2089683356 @default.
• W2084060246 cites W2097870088 @default.
• W2084060246 cites W2107295258 @default.
• W2084060246 cites W2116404316 @default.
• W2084060246 cites W2135020991 @default.
• W2084060246 cites W2145167597 @default.
• W2084060246 cites W2149551498 @default.
• W2084060246 cites W2155121555 @default.
• W2084060246 cites W2160390128 @default.
• W2084060246 cites W2160452475 @default.
• W2084060246 cites W2164576143 @default.
• W2084060246 cites W4241717103 @default.
• W2084060246 cites W424467158 @default.
• W2084060246 cites W78064851 @default.
• W2084060246 doi "https://doi.org/10.1016/j.jacl.2007.12.004" @default.
• W2084060246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21291711" @default.
• W2084060246 hasPublicationYear "2008" @default.
• W2084060246 type Work @default.
• W2084060246 sameAs 2084060246 @default.
• W2084060246 citedByCount "12" @default.
• W2084060246 countsByYear W20840602462012 @default.
• W2084060246 countsByYear W20840602462013 @default.
• W2084060246 countsByYear W20840602462014 @default.
• W2084060246 countsByYear W20840602462015 @default.
• W2084060246 countsByYear W20840602462018 @default.
• W2084060246 countsByYear W20840602462020 @default.
• W2084060246 countsByYear W20840602462021 @default.
• W2084060246 crossrefType "journal-article" @default.
• W2084060246 hasAuthorship W2084060246A5008726377 @default.
• W2084060246 hasAuthorship W2084060246A5011389314 @default.
• W2084060246 hasAuthorship W2084060246A5023716582 @default.
• W2084060246 hasAuthorship W2084060246A5062468141 @default.
• W2084060246 hasAuthorship W2084060246A5080916339 @default.
• W2084060246 hasAuthorship W2084060246A5086425417 @default.
• W2084060246 hasAuthorship W2084060246A5090460841 @default.
• W2084060246 hasConcept C126322002 @default.
• W2084060246 hasConcept C134018914 @default.
• W2084060246 hasConcept C2776329913 @default.
• W2084060246 hasConcept C2776839432 @default.
• W2084060246 hasConcept C2777180221 @default.
• W2084060246 hasConcept C2777482532 @default.
• W2084060246 hasConcept C2778163477 @default.
• W2084060246 hasConcept C2778657065 @default.
• W2084060246 hasConcept C2780072125 @default.
• W2084060246 hasConcept C555293320 @default.
• W2084060246 hasConcept C62746215 @default.
• W2084060246 hasConcept C71924100 @default.
• W2084060246 hasConcept C98274493 @default.
• W2084060246 hasConceptScore W2084060246C126322002 @default.
• W2084060246 hasConceptScore W2084060246C134018914 @default.
• W2084060246 hasConceptScore W2084060246C2776329913 @default.
• W2084060246 hasConceptScore W2084060246C2776839432 @default.
• W2084060246 hasConceptScore W2084060246C2777180221 @default.
• W2084060246 hasConceptScore W2084060246C2777482532 @default.
• W2084060246 hasConceptScore W2084060246C2778163477 @default.
• W2084060246 hasConceptScore W2084060246C2778657065 @default.
• W2084060246 hasConceptScore W2084060246C2780072125 @default.
• W2084060246 hasConceptScore W2084060246C555293320 @default.
• W2084060246 hasConceptScore W2084060246C62746215 @default.
• W2084060246 hasConceptScore W2084060246C71924100 @default.
• W2084060246 hasConceptScore W2084060246C98274493 @default.
• W2084060246 hasIssue "1" @default.
• W2084060246 hasLocation W20840602461 @default.
• W2084060246 hasLocation W20840602462 @default.
• W2084060246 hasOpenAccess W2084060246 @default.
• W2084060246 hasPrimaryLocation W20840602461 @default.
• W2084060246 hasRelatedWork W2055835176 @default.
• W2084060246 hasRelatedWork W2084060246 @default.
• W2084060246 hasRelatedWork W2123793996 @default.
• W2084060246 hasRelatedWork W2158755028 @default.
• W2084060246 hasRelatedWork W2163230619 @default.

• next